The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Treatment approaches for AL amyloidosis versus ATTR amyloidosis
Efstathios Kastritis, MD, University of Athens, Athens, Greece, discusses different treatment approaches for light chain (AL) amyloidosis versus transthyretin (ATTR) amyloidosis, emphasizing the importance of accurately diagnosing patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
